Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

By afschroeder • April 27, 2026

Muñoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp MS, Houot R, Beitinjaneh A, Zheng D, Chang M, Zhang W, Shen RR, Khalid RD, Kloos I, Wang ML. Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2. J Hematol Oncol. 2026 Apr 27. doi: 10.1186/s13045-026-01797-4. Epub ahead of print. PMID: 42036693.

Tags: Brexu-cel, CAR T-cell therapy, Hematology/Oncology, Long-term follow-up, Mantle cell lymphoma, Publications, ZUMA-2

Medical Societies in the United States: History, Purpose, Challenge, and Future Directions

Schiller G, Leer LR. Medical Societies in the United States: History, Purpose, Challenge, and Future Directions. Cureus. 2026 Jul 10;18(7):e112407. doi: 10.7759/cureus.112407. PMID: 42572655; PMCID:[...]

Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?

Margolis S, Guirguis AN, Lee C, Smith S, LeVee A, Lipsyc-Sharf MD, Bardia A, Sedrak MS. Patient-reported outcomes in clinical trials leading to breast cancer[...]

Editorial Expression of Concern: Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

Hsu JH, Shi Y, Frost P, Yan H, Hoang B, Sharma S, Gera J, Lichtenstein A. Editorial Expression of Concern: Interleukin-6 activates phosphoinositol-3' kinase in[...]